Glucotrack (Nasdaq:GCTK) announced today that it intends to participate in a bionic pancreas initiative in Europe.

(Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that ...

Science Connected Magazine is an editorially independent, non-profit newsroom producing open-access science journalism and ...

The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with ...

High school life is a fragile juggling act of managing painstaking amounts of schoolwork, meeting the demands of ...

Advocates say a remote care program launched by Ochsner Health helps primary care physicians better manage patients with ...

Eating salad might not be as healthy as you think. Discover why your daily greens could spike your blood sugar and how to fix ...

Dexcom has been cash flow positive for since 2014 and more recently moved into positive earnings territory. While revenue has grown very quickly, research and development expenses and selling, general ...

Michael W. Schwartz explains the role played by the brain as a cause of elevated blood sugar and related metabolic derangements in type 1 diabetes ...

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

DexCom stock was on the rise Thursday after the maker of medical technology said it had received clearance from the U.S. Food ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...